Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | YES1 | P07947 | 1/20 | 0.52 |
| ▸ | HCK | P08631 | 1/20 | 0.49 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697875 | 0.94 | BRAF (0.55) | BRAFCYP2C9RAF1YES1HCK | |
| SCHEMBL1697964 | 0.92 | BRAF (0.57) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697949 | 0.90 | BRAF (0.59) | BRAFCYP2C9RAF1YES1HCK | |
| SCHEMBL1698055 | 0.89 | BRAF (0.57) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1698088 | 0.88 | BRAF (0.52) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697957 | 0.88 | BRAF (0.52) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697892 | 0.88 | BRAF (0.56) | BRAFCYP2C9RAF1YES1HCK | |
| SCHEMBL1697947 | 0.87 | BRAF (0.57) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697965 | 0.87 | BRAF (0.51) | BRAFCYP2C9RAF1YES1HCK | |
| SCHEMBL1698046 | 0.87 | BRAF (0.49) | BRAFCYP2C9RAF1YES1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576566-B1 | THIENO(2,3B)PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | MERCK SHARP & DOHME (NL) | 2015-10-28 | — | — | EP | disclosed |
| EP-2576566-B1 | THIENO(2,3B)PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | MERCK SHARP & DOHME (NL) | 2015-10-28 | — | — | EP | disclosed |
| US-8669256-B2 | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity | MERCK SHARP & DOHME B.V. (NL) | 2014-03-11 | — | — | US | disclosed |
| US-8669256-B2 | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity | MERCK SHARP & DOHME B.V. (NL) | 2014-03-11 | — | — | US | disclosed |
| EP-2576566-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | MSD Oss B.V. (NL) | 2013-04-10 | — | — | EP | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| WO-2011147764-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | N.V. ORGANON (NL) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147764-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | N.V. ORGANON (NL) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885CYP2C9 1920/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.